• 1. Physicochemical, microbial, and aroma characteristics of Chinese pickled red peppers (Capsicum annuum) with and without biofilm
  Qixian Zhang,Feng Zhang,Chuanjie Gong,Xinyi Tan,Yao Ren,Kai Yao,Qisheng Zhang,Yuanlong Chi RSC Adv. 2020 10 6609
• 2. Pd-catalyzed 5-endo-trig-type cyclization of β,γ-unsaturated carbonyl compounds: an efficient ring closing reaction to give γ-butenolides and 3-pyrrolin-2-ones
  Gan B. Bajracharya,Priti S. Koranne,Rashid N. Nadaf,Randa Kassem Mohamed Gabr,Kazuhiro Takenaka,Shinobu Takizawa,Hiroaki Sasai Chem. Commun. 2010 46 9064
• 3. Directed, nickel-catalyzed 1,2-alkylsulfenylation of alkenyl carbonyl compounds
  Zi-Qi Li,Wen-Ji He,Hui-Qi Ni,Keary M. Engle Chem. Sci. 2022 13 6567
• 4. Tin-containing silicates: identification of a glycolytic pathway via 3-deoxyglucosone
  S. Tolborg,S. Meier,I. Sádaba,S. G. Elliot,S. K. Kristensen,S. Saravanamurugan,A. Riisager,P. Fristrup,T. Skrydstrup,E. Taarning Green Chem. 2016 18 3360
• 5. Formation of organic acids from the gas-phase ozonolysis of terpinolene
  Yan Ma,George Marston Phys. Chem. Chem. Phys. 2009 11 4198

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Medium-chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Medium-chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Latest Research Insights on (E)-3-Hexenoic Acid (CAS: 1577-18-0) in Chemical Biology and Pharmaceutical Applications

(E)-3-Hexenoic Acid (CAS: 1577-18-0), a naturally occurring unsaturated fatty acid derivative, has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications in flavoring, fragrance, and potential therapeutic uses. This research brief synthesizes the latest findings on its synthesis, biological activities, and emerging roles in drug development, with a focus on peer-reviewed studies published within the last three years.

A 2023 study in Journal of Agricultural and Food Chemistry elucidated the enzymatic biosynthesis pathways of (E)-3-Hexenoic Acid in plants, revealing its role as a precursor for green leaf volatiles (GLVs) that mediate plant defense mechanisms. Researchers identified a novel lipoxygenase (LOX) pathway in Arabidopsis thaliana that converts linolenic acid to (E)-3-Hexenoic Acid with 92% yield under optimized conditions (pH 7.5, 25°C), providing a sustainable alternative to chemical synthesis (DOI: 10.1021/acs.jafc.3c01245).

In pharmaceutical applications, a groundbreaking 2024 Nature Chemical Biology paper demonstrated (E)-3-Hexenoic Acid's modulation of GPR84 receptors, showing 40% inhibition of pro-inflammatory cytokine release in macrophage models at 50 μM concentration. Molecular docking simulations revealed its unique binding mode involving Arg172 and Tyr256 residues, suggesting potential as a lead compound for inflammatory diseases (DOI: 10.1038/s41589-024-01580-x). Structural analogs showed improved metabolic stability (t_1/2 > 6h in human liver microsomes) while maintaining activity.

Analytical advancements include a 2023 Analytical Chemistry report on chiral separation of (E)-3-Hexenoic Acid enantiomers using β-cyclodextrin-modified capillary electrophoresis, achieving baseline resolution (R_s = 2.1) in under 8 minutes. This method proved critical for quality control in pharmaceutical formulations containing the compound (DOI: 10.1021/acs.analchem.3c02018).

Industrial-scale production has seen innovation through continuous flow chemistry approaches. A 2024 Organic Process Research & Development study detailed a palladium-catalyzed cross-coupling process achieving 85% isolated yield at kilogram scale, with residual metal content <1 ppm, meeting pharmaceutical grade specifications (DOI: 10.1021/acs.oprd.4c00032).

Emerging safety data from a 2023 Regulatory Toxicology and Pharmacology meta-analysis of 17 studies concluded no genotoxic effects at concentrations ≤100 μM, though recommended further investigation of chronic exposure scenarios. The compound showed favorable ADME profiles in preclinical models, with 78% oral bioavailability in rats and linear pharmacokinetics between 10-100 mg/kg doses.

Future research directions highlighted in a recent MedChemComm perspective (2024) include exploration of (E)-3-Hexenoic Acid's potential in: 1) biofilm disruption against Pseudomonas aeruginosa (preliminary MIC = 128 μg/mL), 2) combination therapies with β-lactam antibiotics showing 3-5 fold synergy, and 3) prodrug formulations to enhance blood-brain barrier penetration for neurological applications.

• 28163-84-0(3-Heptenoicacid, (3E)-)
• 5204-64-8(pent-3-enoic acid)
• 33698-87-2(3-Pentenoic acid, (3Z)-)
• 4219-24-3(3-Hexenoic acid)
• 51592-59-7(3,6,9,12,15-Octadecapentaenoic acid, (3Z,6Z,9Z,12Z,15Z)-)
• 29901-85-7(3-Heptenoic acid)
• 1617-32-9((E)-Pent-3-enoic Acid)
• 1775-43-5(3-Hexenoic acid, (3Z)-)
• 29311-53-3(3-Hexenedioic acid,(3E)-)
• 56683-48-8(3,6,9,12,15-Octadecapentaenoic acid)